Insmed climbs after Morgan Stanley upgrades to 'overweight,' hikes PT

Insmed

30/03/2026 12:39

** Shares of drugmaker Insmed INSM.O up 3.8% at $150.82 premarket

** Morgan Stanley upgrades rating to "overweight" from "equal-weight"; raises price target to $212.00 from $166.00

** New PT implies ~48% upside from the stocks last close

** Brokerage says Brinsupri, Insmed’s new pill for the chronic lung disease bronchiectasis is gaining traction faster than expected. Doctors are growing more confident and prescription is broadening for the drug that helps reduce lung inflammation

** Morgan Stanley cites proprietary survey showing 85% of U.S. pulmonologists have already prescribed Brinsupri, with patient share expected to nearly double by year‑end

** As of last close, INSM stock down 16.5% YTD

 (Reporting by Tharuniyaa Lakshmi in Bengaluru)

 ((tharuniyaa@thomsonreuters.com))